Precision BioSciences (NASDAQ:DTIL) Share Price Crosses Below 50-Day Moving Average - Here's What Happened

Precision BioSciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Precision BioSciences shares fell below their 50-day moving average of $7.00, reaching $6.73 before last trading at $6.91; the stock was down 2.7%.
  • Analyst views are mixed, but MarketBeat reports a “Moderate Buy” consensus and an average price target of $32.25.
  • The company reported a quarterly loss of $0.28 per share, narrower than analysts’ expected loss of $0.85.
  • MarketBeat previews the top five stocks to own by December 1st.

Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) crossed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $7.00 and traded as low as $6.73. Precision BioSciences shares last traded at $6.91, with a volume of 269,139 shares.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on DTIL shares. Wall Street Zen raised Precision BioSciences from a "sell" rating to a "hold" rating in a report on Saturday, November 7th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Precision BioSciences in a research note on Tuesday, November 3rd. Finally, HC Wainwright reiterated a "buy" rating on shares of Precision BioSciences in a report on Monday, August 3rd. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $32.25.

Check Out Our Latest Analysis on Precision BioSciences

Precision BioSciences Stock Down 2.7%

The company has a debt-to-equity ratio of 0.43, a current ratio of 10.47 and a quick ratio of 10.47. The company has a market cap of $193.07 million, a price-to-earnings ratio of -5.57 and a beta of 1.34. The firm's 50 day simple moving average is $7.00 and its 200-day simple moving average is $6.79.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last posted its earnings results on Tuesday, November 3rd. The company reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.85) by $0.57. Precision BioSciences had a negative return on equity of 56.69% and a negative net margin of 96.73%. As a group, sell-side analysts anticipate that Precision BioSciences, Inc. will post -2.28 earnings per share for the current year.

Institutional Investors Weigh In On Precision BioSciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Octagon Capital Advisors LP grew its position in shares of Precision BioSciences by 16.6% during the first quarter. Octagon Capital Advisors LP now owns 2,236,732 shares of the company's stock worth $12,302,000 after acquiring an additional 318,737 shares during the last quarter. Affinity Asset Advisors LLC purchased a new stake in Precision BioSciences in the 1st quarter valued at $3,289,000. Corient Private Wealth LP raised its position in Precision BioSciences by 70.4% in the 2nd quarter. Corient Private Wealth LP now owns 245,058 shares of the company's stock valued at $1,926,000 after purchasing an additional 101,206 shares during the last quarter. Marshall Wace LLP acquired a new stake in Precision BioSciences during the 3rd quarter worth $1,016,000. Finally, Squarepoint Ops LLC boosted its stake in Precision BioSciences by 212.7% during the 2nd quarter. Squarepoint Ops LLC now owns 137,106 shares of the company's stock worth $1,078,000 after purchasing an additional 93,258 shares during the period. Hedge funds and other institutional investors own 37.99% of the company's stock.

Precision BioSciences Company Profile

(Get Free Report)

Precision BioSciences is a biotechnology company developing gene-editing therapies using its proprietary ARCUS platform. The platform is designed to make targeted changes to DNA and is being applied to investigational treatments for genetic and infectious diseases. The company's programs include PBGENE-HBV, an investigational therapy designed to target hepatitis B virus DNA, and PBGENE-DMD, a gene-editing program for Duchenne muscular dystrophy. These candidates remain in development and are not approved treatments.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Precision BioSciences Right Now?

Before you consider Precision BioSciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precision BioSciences wasn't on the list.

While Precision BioSciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines